AR110251A1 - Una sal maleato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, formulaciones farmacéuticas, métodos de fabricación y usos de la misma - Google Patents
Una sal maleato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, formulaciones farmacéuticas, métodos de fabricación y usos de la mismaInfo
- Publication number
- AR110251A1 AR110251A1 ARP170103304A ARP170103304A AR110251A1 AR 110251 A1 AR110251 A1 AR 110251A1 AR P170103304 A ARP170103304 A AR P170103304A AR P170103304 A ARP170103304 A AR P170103304A AR 110251 A1 AR110251 A1 AR 110251A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- maleate salt
- acetamide
- free base
- pharmaceutical formulations
- Prior art date
Links
- 150000002688 maleic acid derivatives Chemical class 0.000 title abstract 6
- 239000012458 free base Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 title 2
- 238000000034 method Methods 0.000 abstract 5
- 150000003839 salts Chemical class 0.000 abstract 3
- IVZKZONQVYTCKC-UHFFFAOYSA-N bay 57-1293 Chemical compound N=1C(C)=C(S(N)(=O)=O)SC=1N(C)C(=O)CC(C=C1)=CC=C1C1=CC=CC=N1 IVZKZONQVYTCKC-UHFFFAOYSA-N 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 abstract 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 abstract 1
- 241000700584 Simplexvirus Species 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Agentes antivirales activos, particularmente a sales, más particularmente a una sal maleato de la base libre de N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)-fenil]-acetamida, a sus formulaciones farmacéuticas así como métodos para la producción de estás sales. El uso de estás sales y de sus formulaciones farmacéuticas respectivas en métodos de tratamiento y/o prevención de infecciones con el virus herpes simple humano, particularmente infecciones causadas por HSV-1 y HSV-2. Reivindicación 2: La sal maleato de acuerdo con la reivindicación 1, en donde dicha sal maleato se caracteriza por una fotoestabilidad de al menos el 70% de la base libre residual de N-[5-(amino-sulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil]acetamida después de la exposición a la luz con longitudes de onda que varían como de 300 nm a 800 nm, y con una cantidad de exposición a la luz de al menos 1,2 millones de Lux-hora, y con una energía de exposición a la luz de al menos 200 Wh/m² durante al menos 29 horas cuando dicha fotoestabilidad se determina usando un método según Ph. Eur y/o USP. Reivindicación 3: La sal maleato de acuerdo con una cualquiera de las reivindicaciones anteriores, en donde dicha sal maleato se caracteriza adicionalmente por tener picos característicos de XRPD a 6,6, 15,9, 16,2, 18,1, 20,5, 22,5, 26,1 y 28,6 2q cuando se determina usando un método de compendio según los métodos Ph. Eur y/o USP.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16201009 | 2016-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110251A1 true AR110251A1 (es) | 2019-03-13 |
Family
ID=57421722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170103304A AR110251A1 (es) | 2016-11-28 | 2017-11-28 | Una sal maleato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, formulaciones farmacéuticas, métodos de fabricación y usos de la misma |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11266636B2 (es) |
| EP (2) | EP3892620A1 (es) |
| JP (3) | JP7316214B2 (es) |
| CN (3) | CN110062755B (es) |
| AR (1) | AR110251A1 (es) |
| AU (4) | AU2017365639C1 (es) |
| CA (3) | CA3253285A1 (es) |
| ES (1) | ES2877854T3 (es) |
| HU (1) | HUE054845T2 (es) |
| PL (1) | PL3544977T3 (es) |
| PT (1) | PT3544977T (es) |
| TW (3) | TWI860744B (es) |
| UY (1) | UY37498A (es) |
| WO (1) | WO2018096177A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2573085A1 (en) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
| UY40935A (es) * | 2016-11-28 | 2024-10-31 | Aicuris Gmbh & Co Kg | Composición tópica de hemihidrato de la base libre de n-[5(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]acetamida |
| AR110251A1 (es) * | 2016-11-28 | 2019-03-13 | Aicuris Anti Infective Cures Gmbh | Una sal maleato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, formulaciones farmacéuticas, métodos de fabricación y usos de la misma |
| DK3692039T3 (da) | 2017-10-05 | 2023-03-13 | Innovative Molecules Gmbh | Enantiomerer af substituerede thiazoler som antivirale forbindelser |
| TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6944877B1 (en) * | 1999-08-27 | 2005-09-13 | Koninklijke Philips Electronics N.V. | Closed loop addressable advertising system and method of operation |
| DOP2000000109A (es) * | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
| DE10129714A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Topische Anwendung von Thiazolylamiden |
| DE102005014248A1 (de) | 2005-03-30 | 2006-10-05 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid |
| US20100069632A1 (en) * | 2006-07-03 | 2010-03-18 | Sk Chemicals Co., Ltd | Salts of pyrrolopyrimidinone derivatives and process for preparing the same |
| WO2011115173A1 (ja) * | 2010-03-18 | 2011-09-22 | 興和株式会社 | ベンゾチアジン化合物のモノマレイン酸塩 |
| EP2573086A1 (en) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
| EP2598502B1 (en) | 2011-09-26 | 2014-05-14 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations. |
| EP2573085A1 (en) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
| WO2014124978A2 (en) * | 2013-02-12 | 2014-08-21 | Aicuris Gmbh & Co. Kg | Helicase-primase inhibitors for use in a method of treating alzheimer's disease |
| UY40935A (es) * | 2016-11-28 | 2024-10-31 | Aicuris Gmbh & Co Kg | Composición tópica de hemihidrato de la base libre de n-[5(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]acetamida |
| AR110251A1 (es) * | 2016-11-28 | 2019-03-13 | Aicuris Anti Infective Cures Gmbh | Una sal maleato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, formulaciones farmacéuticas, métodos de fabricación y usos de la misma |
-
2017
- 2017-11-28 AR ARP170103304A patent/AR110251A1/es unknown
- 2017-11-28 CN CN201780073159.8A patent/CN110062755B/zh active Active
- 2017-11-28 AU AU2017365639A patent/AU2017365639C1/en active Active
- 2017-11-28 CA CA3253285A patent/CA3253285A1/en active Pending
- 2017-11-28 CN CN202311025223.9A patent/CN117186085A/zh active Pending
- 2017-11-28 TW TW112121637A patent/TWI860744B/zh active
- 2017-11-28 CA CA3253408A patent/CA3253408A1/en active Pending
- 2017-11-28 JP JP2019528126A patent/JP7316214B2/ja active Active
- 2017-11-28 HU HUE17816544A patent/HUE054845T2/hu unknown
- 2017-11-28 TW TW106141398A patent/TWI753972B/zh active
- 2017-11-28 WO PCT/EP2017/080695 patent/WO2018096177A1/en not_active Ceased
- 2017-11-28 CN CN202311023094.XA patent/CN117186084A/zh active Pending
- 2017-11-28 TW TW111100053A patent/TWI808591B/zh active
- 2017-11-28 EP EP21174191.3A patent/EP3892620A1/en active Pending
- 2017-11-28 PL PL17816544T patent/PL3544977T3/pl unknown
- 2017-11-28 CA CA3045063A patent/CA3045063A1/en active Pending
- 2017-11-28 PT PT178165445T patent/PT3544977T/pt unknown
- 2017-11-28 US US16/464,189 patent/US11266636B2/en active Active
- 2017-11-28 UY UY0001037498A patent/UY37498A/es active IP Right Grant
- 2017-11-28 EP EP17816544.5A patent/EP3544977B1/en active Active
- 2017-11-28 ES ES17816544T patent/ES2877854T3/es active Active
-
2021
- 2021-05-10 AU AU2021202942A patent/AU2021202942C1/en active Active
-
2022
- 2022-01-21 AU AU2022200409A patent/AU2022200409C1/en active Active
- 2022-01-26 US US17/585,145 patent/US12070451B2/en active Active
- 2022-07-14 JP JP2022113134A patent/JP2022145700A/ja active Pending
-
2023
- 2023-02-13 AU AU2023200773A patent/AU2023200773C1/en active Active
-
2024
- 2024-06-24 US US18/751,439 patent/US20240350468A1/en active Pending
- 2024-11-25 JP JP2024204953A patent/JP2025036423A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020003378A1 (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington | |
| AR065797A1 (es) | Usos y derivados de 1-(2- (2,4- dimetilfenilsulfanil) fenil) piperazina | |
| CL2023001299A1 (es) | Procedimiento de fabricación de un inhibidor pd-1/pd-l1 y de sus sales y formas cristalinas de los mismos. | |
| CL2017000469A1 (es) | Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 | |
| CL2018003291A1 (es) | Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018). | |
| CL2022002386A1 (es) | Compuestos de amino pirimidina fusionados | |
| DOP2021000234A (es) | Pirroles triciclicos condensados como moduladores de alfa-1 antitripsina | |
| AR110249A1 (es) | Hemihidrato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, métodos de fabricación y usos del mismo | |
| MX2021004593A (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana. | |
| UY38263A (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| UY37997A (es) | Agentes antivirales contra la hepatitis b | |
| CL2017002709A1 (es) | Compuestos de pirazolo - y triazolo - pirimidina antivirales contra vsr | |
| MX2023000812A (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| ECSP088217A (es) | Formas de cristal delta y épsilon de mesilato de imatinib | |
| DOP2009000116A (es) | Sales y formas de cristal del 2-metil-2-[4-(3-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2,3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionitrilo | |
| CR20180322A (es) | Compuestos de diamina-arilsulfonamida sustituidos con hidroxialquilamina e hidroxicicloalquilamina con actividad selectiva en canales de sodio activados por voltaje | |
| CY1117962T1 (el) | Υδροχλωρικο αλας 4-[2-[[5-μεθυλο-1-(2- ναφθαλενυλο)-1η- πυραζολ-3-υλ]οξυ]αιθυλο] μορφολινης | |
| MX2019001877A (es) | Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas. | |
| UY37498A (es) | Una sal maleato de la base libre de n-[5-(aminosulfonil)-4-20 metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, formulaciones farmacéuticas, métodos de fabricación y usos de la misma | |
| MX2023012941A (es) | Inhibidor de fosfodiesterasa tipo 5 con liberacion de oxido nitrico. | |
| UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
| CO2024006736A2 (es) | Derivados de 4-fenil-2-(1h-1,2,3-triazol-4-il)piperidin-4-ol como inhibidores de apol1 y métodos para usar los mismos | |
| MX2018003291A (es) | Nuevas estrategias terapeuticas contra el cáncer de sangre. | |
| PE20181522A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| MX390507B (es) | Compuestos de amida y su uso. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |